Refine/Revise Search

Here are some other businesses that you may be interested in:

Asking Price: Not Disclosed

Clinical Stage Oncology Co. for Early Cancer Detec

Not Disclosed, Not Disclosed
Not disclosed

The Company is a clinical-stage oncology company with a platform that combines biospectral impedance and AI/ML for point-of-care cancer detection. The lead product delivers rapid, in-procedure assessment of surgical margins—identifying the presence and location of cancer within minutes. Initial commercialization targets skin cancer, where the lead product can shorten procedures, spare healthy tissue, improve surgeon economics, and enhance outcomes. The Company has also built a compelling breast cancer dataset and plans to deploy the lead product to help dramatically reduce the ~20–25% re-surgery (re-excision) rate in partial mastectomies; the breast program is in line for non-dilutive CPRIT support.The Company has a collaboration with PHC Holdings (formerly Panasonic Healthcare; TSE:6529) to commercialize the lead product. The company anticipates FDA clearance in 2026 and profitability in 2028.Beyond skin and breast, the Company has generated promising data in lung, pancreatic, esophageal, and colon tissue. Follow-on products include a rapid biopsy-assessment device and a needle-based device leveraging the same platform.Use of Proceeds: This round will fund FDA clearance activities and the initial commercial launch of the lead product.NDA is required to receive comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.

Cash Flow $1,091
Revenue $9,498
$ Owner Financing Available

loading...
TOP â–²
Add Businesses and/or Franchises
To Basket For Free Information

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our cookies information for more details.